TipRanks
Capricor Therapeutics (DE:4LN2)
FRANKFURT:4LN2
Germany Market
4LN2
Capricor Therapeutics
RESEARCH TOOLSreports

Capricor Therapeutics (4LN2) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

4LN2 Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
4 Buy
6 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Capricor
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4LN2 Stock 12 Month Forecast

Average Price Target

€23.70
▲(37.65% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is €23.70 with a high forecast of €47.41 and a low forecast of €6.15. The average price target represents a 37.65% change from the last price of €17.22.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","25":"€25","48":"€48","13.5":"€13.5","36.5":"€36.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.40717834,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.70358917,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.14537497,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,13.5,25,36.5,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.872,11.836244487692309,14.800488975384615,17.764733463076922,20.72897795076923,23.69322243846154,26.657466926153845,29.621711413846153,32.58595590153846,35.55020038923077,38.51444487692308,41.478689364615384,44.44293385230769,{"y":47.40717834,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.872,10.012891474615385,11.15378294923077,12.294674423846153,13.435565898461538,14.576457373076924,15.717348847692307,16.858240322307694,17.999131796923077,19.14002327153846,20.280914746153847,21.42180622076923,22.562697695384614,{"y":23.70358917,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.872,8.662259613076923,8.452519226153846,8.24277883923077,8.033038452307693,7.823298065384615,7.613557678461539,7.403817291538461,7.194076904615384,6.984336517692308,6.774596130769231,6.564855743846154,6.355115356923077,{"y":6.14537497,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.24,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.495,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.98,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.389,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.872,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€47.41Average Price Target€23.70Lowest Price Target€6.15
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
B. Riley Securities Analyst forecast on DE:4LN2
Madison Elsaadi
B. Riley Securities
B. Riley Securities
€4.39→€18.44
Buy
7.06%
Upside
Upgraded
09/14/26
Capricor Therapeutics upgraded to Buy from Neutral at B. RileyCapricor Therapeutics upgraded to Buy from Neutral at B. Riley
Piper Sandler Analyst forecast on DE:4LN2
Edward Tenthoff
Piper Sandler
Piper Sandler
€1.76→€21.95
Buy
27.46%
Upside
Upgraded
09/01/26
Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Helus Pharma (NASDAQ: HELP)
Oppenheimer Analyst forecast on DE:4LN2
Leland Gershell
Oppenheimer
Oppenheimer
€47.41
Buy
175.30%
Upside
Upgraded
08/25/26
Capricor Therapeutics upgraded to Outperform from Perform at OppenheimerCapricor Therapeutics upgraded to Outperform from Perform at Oppenheimer
Roth MKM Analyst forecast on DE:4LN2
Boobalan Pachaiyappan
Roth MKM
Roth MKM
€6.15
Hold
-64.31%
Downside
Reiterated
08/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR), Ansell (Other OTC: ANSLF) and Erasca (NASDAQ: ERAS)
H.C. Wainwright Analyst forecast on DE:4LN2
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
08/24/26
Wainwright says Capricor's regulatory risk still high after FDA PDUFA extensionWainwright says Capricor's regulatory risk still high after FDA PDUFA extension
JonesTrading Analyst forecast on DE:4LN2
Catherine Novack
JonesTrading
JonesTrading
―
Hold
―
Reiterated
08/17/26
Cantor Fitzgerald Analyst forecast on DE:4LN2
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€3.07→€24.58
Buy
42.75%
Upside
Upgraded
08/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR), Minerva Neurosciences (NASDAQ: NERV) and Bio-Techne (NASDAQ: TECH)
Maxim Group Analyst forecast on DE:4LN2
Jason McCarthy
Maxim Group
Maxim Group
―
Hold
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Mediwound (NASDAQ: MDWD) and Capricor Therapeutics (NASDAQ: CAPR)
Alliance Global Partners Analyst forecast on DE:4LN2
Matthew Venezia
Alliance Global Partners
Alliance Global Partners
€44.77→
Hold
―
Reiterated
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at Alliance GlobalCapricor Therapeutics downgraded to Neutral from Buy at Alliance Global
Ladenburg Thalmann & Co. Analyst forecast on DE:4LN2
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at LadenburgCapricor Therapeutics downgraded to Neutral from Buy at Ladenburg
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
B. Riley Securities Analyst forecast on DE:4LN2
Madison Elsaadi
B. Riley Securities
B. Riley Securities
€4.39→€18.44
Buy
7.06%
Upside
Upgraded
09/14/26
Capricor Therapeutics upgraded to Buy from Neutral at B. RileyCapricor Therapeutics upgraded to Buy from Neutral at B. Riley
Piper Sandler Analyst forecast on DE:4LN2
Edward Tenthoff
Piper Sandler
Piper Sandler
€1.76→€21.95
Buy
27.46%
Upside
Upgraded
09/01/26
Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Helus Pharma (NASDAQ: HELP)
Oppenheimer Analyst forecast on DE:4LN2
Leland Gershell
Oppenheimer
Oppenheimer
€47.41
Buy
175.30%
Upside
Upgraded
08/25/26
Capricor Therapeutics upgraded to Outperform from Perform at OppenheimerCapricor Therapeutics upgraded to Outperform from Perform at Oppenheimer
Roth MKM Analyst forecast on DE:4LN2
Boobalan Pachaiyappan
Roth MKM
Roth MKM
€6.15
Hold
-64.31%
Downside
Reiterated
08/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR), Ansell (Other OTC: ANSLF) and Erasca (NASDAQ: ERAS)
H.C. Wainwright Analyst forecast on DE:4LN2
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
08/24/26
Wainwright says Capricor's regulatory risk still high after FDA PDUFA extensionWainwright says Capricor's regulatory risk still high after FDA PDUFA extension
JonesTrading Analyst forecast on DE:4LN2
Catherine Novack
JonesTrading
JonesTrading
―
Hold
―
Reiterated
08/17/26
Cantor Fitzgerald Analyst forecast on DE:4LN2
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
€3.07→€24.58
Buy
42.75%
Upside
Upgraded
08/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR), Minerva Neurosciences (NASDAQ: NERV) and Bio-Techne (NASDAQ: TECH)
Maxim Group Analyst forecast on DE:4LN2
Jason McCarthy
Maxim Group
Maxim Group
―
Hold
―
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Mediwound (NASDAQ: MDWD) and Capricor Therapeutics (NASDAQ: CAPR)
Alliance Global Partners Analyst forecast on DE:4LN2
Matthew Venezia
Alliance Global Partners
Alliance Global Partners
€44.77→
Hold
―
Reiterated
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at Alliance GlobalCapricor Therapeutics downgraded to Neutral from Buy at Alliance Global
Ladenburg Thalmann & Co. Analyst forecast on DE:4LN2
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at LadenburgCapricor Therapeutics downgraded to Neutral from Buy at Ladenburg
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
CELCCelcuity
ONCBeOne Medicines
GHGuardant Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Capricor Therapeutics

3 Months
Kristen KluskaCantor Fitzgerald
Success Rate
6/14 ratings generated profit
43%
Average Return
+21.86%
Copying Kristen Kluska's trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +21.86% per trade.
1 Year
Kristen KluskaCantor Fitzgerald
Success Rate
8/14 ratings generated profit
57%
Average Return
+61.30%
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +61.30% per trade.
2 Years
Kristen KluskaCantor Fitzgerald
Success Rate
4/14 ratings generated profit
29%
Average Return
+31.45%
Copying Kristen Kluska's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of +31.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4LN2 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
17
12
15
7
7
Buy
8
4
4
1
1
Hold
0
0
10
17
17
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
16
29
25
25
In the current month, 4LN2 has received 8 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. 4LN2 average Analyst price target in the past 3 months is 23.70.
Each month's total comprises the sum of three months' worth of ratings.

4LN2 Financial Forecast

4LN2 Earnings Forecast

Next quarter’s earnings estimate for 4LN2 is -€0.12 with a range of -€0.65 to €1.95. The previous quarter’s EPS was -€0.60. 4LN2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4LN2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 4LN2 is -€0.12 with a range of -€0.65 to €1.95. The previous quarter’s EPS was -€0.60. 4LN2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4LN2 has Performed in-line its overall industry.

4LN2 Sales Forecast

Next quarter’s sales forecast for 4LN2 is €35.76M with a range of €0.00 to €171.47M. The previous quarter’s sales results were €0.00. 4LN2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4LN2 has Performed in-line its overall industry.
Next quarter’s sales forecast for 4LN2 is €35.76M with a range of €0.00 to €171.47M. The previous quarter’s sales results were €0.00. 4LN2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4LN2 has Performed in-line its overall industry.

4LN2 Stock Forecast FAQ

What is DE:4LN2’s average 12-month price target, according to analysts?
Based on analyst ratings, Capricor Therapeutics’s 12-month average price target is 23.70.
    What is DE:4LN2’s upside potential, based on the analysts’ average price target?
    Capricor Therapeutics has 37.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Capricor Therapeutics a Buy, Sell or Hold?
          Capricor Therapeutics has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Capricor Therapeutics’s share price target?
            The average share price target for Capricor Therapeutics is 23.70. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €47.41 ,and the lowest forecast is €6.15. The average share price target represents 37.65% Increase from the current price of €17.22.
              What do analysts say about Capricor Therapeutics?
              Capricor Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Capricor Therapeutics?
                To buy shares of DE:4LN2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.